GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Deferred Policy Acquisition Costs

Xintela AB (OSTO:XINT) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Xintela AB (OSTO:XINT) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Medicon Village, Lund, SWE, 22381
Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.